The current study was performed to determine whether access to facilities performing accelerated partial breast irradiation (APBI) is associated with differences in the use of adjuvant radiotherapy (RT). METHODS: Using the National Cancer Data Base, the authors performed a retrospective study of women aged 50 years who were diagnosed with early-stage breast cancer between 2004 and 2013 and treated with breast-conserving surgery (BCS). Facilities performing APBI in 10% of their eligible patients within a given year were defined as APBI facilities whereas those not performing APBI were defined as non-APBI facilities. All other facilities were excluded. The authors identified independent factors associated with RT use using multivariable logistic regression with clustering in the overall sample as well as in subsets of patients with standard-risk invasive cancer, low-risk invasive cancer, and ductal carcinoma in situ. RESULTS: Among 222,544 patients, 76.6% underwent BCS plus RT and 23.4% underwent BCS alone. The likelihood of RT receipt in the overall sample did not appear to differ significantly between APBI and non-APBI facilities (adjusted odds ratio [AOR], 1.02; P 5.61). Subgroup multivariable analysis demonstrated that among patients with standard-risk invasive cancer, there was no association between evaluation at an APBI facility and receipt of RT (AOR, 0.98; P 5.69). However, patients with low-risk invasive cancer were found to be significantly more likely to receive RT (54.4% vs 59.5%; AOR, 1.22 [P<.001]), whereas patients with ductal carcinoma in situ were less likely to receive RT (56.9% vs 55.3%; AOR, 0.89 [P 5.04]) at APBI facilities. CONCLUSIONS: Patients who were eligible for observation were more likely to receive RT in APBI facilities but no difference was observed among patients with standard-risk invasive cancer who would most benefit from RT. Cancer 2017;123:502-11.
INTRODUCTION
Radiotherapy (RT) reduces the risk of disease recurrence after breast-conserving surgery (BCS) for patients with ductal carcinoma in situ (DCIS) or invasive breast cancer, and improves survival among patients with invasive disease. 1, 2 Despite these benefits, the use of RT remains inconsistent, with 15% to 30% of patients not receiving adjuvant RT. [3] [4] [5] In part, this is because of the inconvenience of daily treatment visits over several weeks. 6 Accelerated partial breast irradiation (APBI), with its shortened schedule of 1 week, has been proposed as a potential solution for improving the use of RT after BCS. 6 APBI delivers RT to the tumor bed using external-beam RT (EBRT) or brachytherapy techniques, treating the percentage of the breast at highest risk of developing local disease recurrence after BCS. [7] [8] [9] Although to the best of our knowledge long-term randomized evidence demonstrating the equivalence of whole-breast irradiation (WBI) and APBI is not available, there is enthusiasm for APBI. This is partially derived from the hope that its convenience may make RT available to a greater number of patients, although to our knowledge data regarding the efficacy and toxicity of APBI are inconsistent. [10] [11] [12] However, to our knowledge the relation between APBI access and RT use after BCS has not been investigated to date, and as such it is unclear whether the widespread implementation of APBI, which followed the introduction of the MammoSite balloon catheter in 2001 (Hologic Inc, Marlborough, Mass), has led to more consistent RT use. In addition, the impact of APBI among patients belonging to different risk groups is unclear. Since the initial publication of Cancer and Leukemia Group B (CALGB) 9343 in the year this study period began, 13 there has been an appreciation that elderly women derive minimal benefit from RT, and as such the use of RT among women with estrogen receptor (ER)-positive disease is not a desirable outcome on a population level. Women aged > 70 years with ER-positive disease and small tumors (eg, patients eligible for CALGB-9343) are among those considered suitable for APBI off trial according to the American Society for Radiation Oncology (ASTRO) consensus guidelines.
14 As such, it is possible that some practices may feel more comfortable offering APBI to women aged 70 years, despite their candidacy for omission of RT. Therefore, it is unclear whether the adoption of APBI results in a skewed increase in RT use toward a lower-risk population, as the guidelines may indicate. However, given that one of the potential benefits of APBI is its lower burden on the patient, it also may be possible that APBI could increase RT use among patients who would most benefit from it, such as those with standardrisk early-stage breast cancer. To address these knowledge gaps, we first assessed the association between evaluation at an APBI facility and RT use overall. We then evaluated this association between APBI access and RT use in specific subgroups of patients, including those with standardrisk invasive cancer and low-risk invasive cancer, and patients with DCIS. Finally, we assessed trends in the use of various RT modalities over time to determine their individual association with RT use.
MATERIALS AND METHODS

Data Source and Study Population
We used the National Cancer Data Base (NCDB) to examine the receipt of adjuvant RT among patients with early-stage breast cancer. The NCDB is a joint project of the American Cancer Society and the American College of Surgeons Commission on Cancer. The American College of Surgeons has executed a Business Associate Agreement that includes a data use agreement with each of its Commission on Cancer-accredited hospitals. The NCDB, established in 1989, is a nationwide, facilitybased, comprehensive, clinical surveillance resource oncology data set that currently captures 70% of all newly diagnosed malignancies in the United States annually. The data used in the study were derived from a deidentified NCDB file. The American College of Surgeons and the Commission on Cancer have not verified and are not responsible for the analytic or statistical methodology used, or the conclusions drawn from these data by the investigators. The current study was granted an exemption from the Yale Human Investigations Committee.
Inclusion criteria included patients with a diagnosis of breast cancer made between 2004 and 2013. In accordance with currently available APBI guidelines, [14] [15] [16] we restricted the sample to female patients aged 50 years at time of diagnosis with pathologically T1/T2N0 invasive breast cancer and TisN0/NX DCIS who were treated with BCS ( Fig. 1 ) to encompass women who were both cautionary or suitable by the ASTRO guidelines. All tumor sizes were limited to 3 cm in both patients with DCIS and those with invasive breast cancer. We included patients who did not receive any adjuvant RT and patients receiving either APBI or WBI. Based on studies evaluating the use of APBI, we defined APBI as the receipt of either brachytherapy without EBRT or EBRT with the total dose limited to 30 to 40 grays (Gy) in 5 to 10 fractions. [17] [18] [19] Women were excluded from analysis if information regarding RT dose was incomplete (12,388 women). Because brachytherapy typically is used in the APBI setting and the NCDB does not report the dose administered to patients treated with brachytherapy, we included all patients meeting our criteria who received brachytherapy without EBRT. WBI was defined as EBRT with a dose per fraction of 1.5 to 3.0 Gy for 14 to 50 fractions and patients were required to have received a total dose limited to 40 to 66.4 Gy. 20 To take into account small inaccuracies in the recorded dose and number of fractions delivered, hypofractionated WBI (HF-WBI) was broadly defined as a fractional dose of 2.2 to 3.0 Gy whereas conventionally fractionated WBI was broadly defined as a fractional dose of 1.5 to 2.2 Gy. 20 Patients who received treatments not within our defined dosing criteria were excluded. We did not include patients who received regional lymph node RT as reported by the NCDB. Patients receiving stereotactic RT and treatments delivered using electron, neutron, proton beam, or intraoperative RT, or any RT coded as palliative care, were excluded. The reason for the omission of RT was noted.
For subgroup analysis, we divided our sample into 3 subgroups, with the understanding that these groups may differ with regard to the use of adjuvant RT: 1) patients with DCIS; 2) patients meeting the CALGB-9343 trial criteria ("low-risk invasive cancer"); and 3) all other patients with invasive breast cancer meeting our inclusion criteria ("standard-risk invasive cancer"). The criteria used in the CALGB-9343 study included women age 70 years with clinical stage I (T1N0M0) invasive breast cancer with a tumor size 2 cm with ER-positive or unknown receptor status. 21 We also performed a sensitivity analysis in which we divided patients with DCIS into those with "low-risk DCIS" and those with "standard-risk DCIS." Patients with low-risk DCIS were defined as those patients meeting the Radiation Therapy Oncology Group (RTOG) 9804 criteria (low-grade or intermediate-grade DCIS measuring < 2.5 cm), 
Study Covariates and Primary Outcome
The primary outcome was receipt of adjuvant RT. Because APBI can be delivered by EBRT, and the technique for this is contained within the publicly available RTOG 0413-National Surgical Adjuvant Breast and Bowel Project (NSABP) B39 trial, 23 APBI theoretically can be performed at any center that offers EBRT. However, we sought to determine which centers were routinely offering this technique to patients. To determine APBI availability of the evaluating facilities during a given year, we calculated the percentage of RT cases in the study sample performed as APBI for each year in the NCDB. Facilities with a total of 10% APBI cases within a given year were categorized as APBI facilities for that year whereas facilities with no APBI cases within a given year were categorized as non-APBI facilities for that year. We did not include facilities with 0.1% to 9.9% APBI cases within a particular year to reduce the potential for misclassification due to miscoding during data submission to the NCDB. Using this classification schema, a single facility could be classified as an APBI facility for several years and then reclassified as a non-APBI facility, which reflects trends in treatments delivered as practice patterns evolve over time. Our independent variable of APBI availability thus was defined for each patient based on whether APBI was available at the reporting treatment facility during the year of diagnosis. By this schema, approximately 56% of the facilities changed their classification during the study period. Patient demographic and clinical information included as independent variables were age; race; geographic region (Northeast, Midwest, South, and West); type of primary health insurance; percentage of high school graduates within the zip code of residence; whether the patient lived in a metropolitan, urban, or rural location; distance in miles between the patient's residence and the reporting treatment facility; and the number of comorbid conditions as described by the Charlson-Deyo comorbidity score. Facility-level characteristics included evaluating facility type and total breast RT volume. Total breast RT volume was determined by calculating the total number of breast RT cases (APBI and WBI) reported by each facility from 2004 through 2013. High-volume facilities were defined a priori as those belonging in the 90th percentile of total RT volume in any given year, with the remainder aggregated as low-volume facilities. 24 Cancer characteristics assessed included year of cancer diagnosis and tumor differentiation. To control for variations in RT use in different facilities, we performed a sensitivity analysis restricting the sample to patients who received all their RT at the evaluating facility. To account for differences due to our definition of non-APBI facilities, we performed a separate sensitivity analysis wherein we defined non-APBI facilities as those performing APBI in 0% to 9.9% of their RT cases while keeping our definition of APBI facilities as those performing APBI in 10% of their RT cases.
Finally, several post hoc analyses were performed for hypothesis-generating purposes. Subgroup analysis of patients with an increased travel distance from the evaluating facility was performed because we hypothesized that they would likely be most affected by APBI availability. Although a complete analysis of how hypofractionation affects RT use is beyond the scope of the current study, we investigated how temporal trends in the use of APBI and HF-WBI might affect adjuvant RT use for hypothesisgenerating purposes.
Statistical Analysis
Descriptive statistics were used to summarize patient, facility, and cancer characteristics. Bivariate associations of these categorical variables with receipt of RT were tested by the Pearson chi-square test. Covariates with a 2-sided P value of .10 were then included in a multivariable logistic regression model with clustering for facility identification. We tested for multicollinearity for covariates controlled for in the current analysis. The variance inflation factors were all <2, indicating that the assumption of reasonable independence among our predictor variables was met. A 2-sided P value of < .05 was used to determine statistical significance. Stata SE software (version 13.0; StataCorp LP, College Station, Tex) was used to perform all statistical analyses.
RESULTS
Among 222,544 patients, 170,377 (76.6%) were treated with BCS plus RT and 52,167 (23.4%) were treated with BCS alone. A total of 126,088 patients (56.7%) were evaluated at an APBI facility and 96,456 (43.3%) were evaluated at a non-APBI facility (Table 1) . APBI facilities were more likely to be high-volume academic centers, or located in the south (see Supporting Information Table 1 ). Approximately 77.3% of patients at APBI facilities received RT compared with 75.6% of patients at non-APBI facilities (P<.001). On multivariable analysis, evaluation at an APBI facility was no longer found to be significantly associated with the increased use of RT (adjusted odds ratio [AOR], 1.02; 95% confidence interval [95% CI], 0.94-1.11) ( Table 2 ). Factors associated with the increased use of RT included evaluation at high-volume breast RT facilities, nonacademic facilities, and facilities located in the Midwest. Compared with patients in metropolitan areas, those in urban areas were more likely to receive RT (AOR, 1.27; 95% CI, 1.18-1.38). Patients who lived 50 miles from a facility were found to be less likely to receive RT compared with patients living within <50 miles of the facility (AOR, 0.59; 95% CI, 0.55-0.65). Older patients, those without private insurance, minority patients, and those with increased comorbidities were less likely to receive RT. We found that among patients who were treated with BCS alone, 68.3% did not receive RT because RT was not part of the planned first-course treatment and 19.9% did not receive RT because it was recommended by the patient's physician but refused by the patient, the patient's family member, or the patient's guardian. The other 12% of patients did not receive RT because of other reasons, including having contraindications to RT.
When patients were divided into subgroups, 137,234 were classified as having standard-risk invasive cancer, 46,630 were classified as having low-risk invasive cancer, and 38,680 patients were classified as having DCIS. Univariate subgroup analyses demonstrated that 84.3% of patients with standard-risk invasive cancer who were evaluated at APBI facilities received RT in contrast with 82.7% at non-APBI facilities (P<.001) (Fig. 2) . However, no significant difference in RT use by APBI availability was observed in multivariable analysis among patients with standard-risk invasive cancer (AOR, 0.98; 95% CI, 0.89-1.08) ( Table 3 ). In contrast, 65.1% of patients with low-risk invasive cancer received RT when evaluated at APBI facilities whereas 60.2% of patients with low-risk invasive cancer treated at non-APBI facilities received RT (P<.001) (Fig. 2) . Multivariable analysis continued to demonstrate an increase in RT use in patients with low-risk invasive cancer treated in APBI facilities (AOR, 1.22; 95% CI, 1.09-1.36) ( Table 3) . Among patients with DCIS, 67.4% who were evaluated at APBI facilities received RT compared with 68.8% of patients with DCIS treated at non-APBI facilities (P 5 .003) (Fig. 2) . On multivariable analysis, evaluation at APBI facilities continued to be associated with decreased RT use among patients with DCIS (AOR, 0.89; 95% CI, 0.80-0.99) ( Table 3 ). When we risk-stratified patients with DCIS further, we continued to observe decreased RT use among patients with standard-risk DCIS (AOR, 0.88; 95% CI, 0.78-0.98) who were evaluated at APBI facilities, but no change in RT use was noted among patients with low-risk DCIS (AOR, 0.91; 95% CI, 0.80-1.03). Treatment at nonacademic facilities was found to be associated with increased RT use among all subgroups. When we limited our analysis to patients who lived 50 miles from the RT facility, we found that APBI facilities were associated with increased RT use among all patients with invasive cancer but not among those with DCIS (see Supporting Information Table 2 ). The distribution of treatment in APBI and non-APBI facilities varied in the different subgroups, with an increased likelihood of treatment with BCS alone noted among patients with low-risk invasive cancer. When we investigated the percentage of patients receiving RT who were being treated with APBI in APBI facilities, 27.6% of patients with standard-risk invasive cancer who were treated with RT received APBI compared with 25.6% of patients with low-risk invasive cancer and 18.3% of patients with DCIS (Fig. 2) .
Sensitivity analyses demonstrated results similar to those of the main analysis. When we restricted the sample to patients who received all their RT at the evaluating facilities, we continued to observe no change in RT use among patients with standard-risk invasive cancer who were treated at an APBI facility (AOR, 0.92; 95% CI, 0.81-1.04), increased RT use in patients with low-risk invasive cancer (AOR, 1.16; 95% CI, 1.02-1.33 [P 5 .02]), and decreased RT use among patients with DCIS (AOR, 0.85; 95% CI, 0.75-0.96). When we performed a separate sensitivity analysis in which we expanded our definition of non-APBI facilities to include those performing APBI in 0% to 9.9% of their RT cases, we continued to observe no change among patients with standard-risk invasive cancer (AOR, 0.94; 95% CI, 0.85-1.02), continued increased use in patients with low-risk invasive cancer (AOR, 1.19; 95% CI, 1.08-1.32), and no change among patients with DCIS treated at APBI facilities (AOR, 0.91; 95% CI, 0.82-1.00).
We examined temporal trends in the use of RT modalities further. We found that the use of brachytherapy slightly increased in 2009 through 2010 (the APBI guidelines were released in 2009), but dropped during 2011 through 2013, whereas use of hypofractionated wholebreast RT progressively increased throughout the study period (see Supporting Information Fig. 1 ). When we investigated changes in all adjuvant RT use by APBI facility over time, APBI facilities during 2011 through 2013 were found to have a 3% increased use of adjuvant RT compared with non-APBI facilities (see Supporting Information Table 3 alone remained fairly static at 22% to 25% in the study period (see Supporting Information Fig. 1) . A similar pattern in temporal trends of RT modalities was observed in APBI facilities when the analysis was limited to patients with standard-risk invasive cancer (see Supporting Information Fig. 2) ; however, in this case, there was a more substantial decrease in BCS alone noted over time (5%).
DISCUSSION
The results of the current study found no overall difference in adjuvant RT use based on APBI availability in a cohort of patients with early-stage breast cancer. Despite the hope that the use of APBI would lead to increased access to RT after BCS, this hypothesis is not supported by the data from the current study. We found no difference in RT use between APBI facilities and non-APBI facilities in women with standard-risk breast cancer. Inconsistently, we found that APBI facilities were associated with a decreased use of RT in women with DCIS overall, and an increased use of RT in women with low-risk invasive breast cancer.
The data from the current study demonstrated that receipt of RT at an APBI facility increased the likelihood of the delivery of RT to patients with low-risk invasive disease. The CALGB-9343 trial demonstrated that RT did not improve 10-year overall or disease-free survival or decrease the rate of mastectomy for disease recurrence, although a small but statistically significant improvement in locoregional disease recurrence was observed for women receiving RT. 13 In light of these findings, the National Comprehensive Cancer Network amended its breast cancer guidelines in 2005, stating that adjuvant RT may be omitted in this patient population. 25 Given its modest benefits, 26, 27 on a population level, a decrease in RT use for this population is desirable, which was the opposite of what we observed.
The association between increased RT rates and access to APBI facilities in patients with low-risk invasive cancer and a lack of change in use among patients with standard-risk invasive cancer raises questions regarding factors that drive this difference. One possibility is that older women with low-risk disease who are eligible for omission of RT may have been motivated to receive treatment through APBI given the promise of decreased travel Abbreviations: 95% CI, 95% confidence interval; APBI, accelerated partial breast irradiation; DCIS, ductal carcinoma in situ; OR, odds ratio; RT, radiotherapy. a Models included adjustment for facility volume status, facility type, location, age, race, insurance status, educational attainment in zip code of residence, rurality, distance from facility, year of diagnosis, Charlson-Deyo comorbidity score, and tumor grade.
requirements, missed time from work, and a smaller treatment volume, and the perception of lower toxicity. However, APBI may not be as appealing to younger patients with standard-risk disease, for whom WBI has a proven survival benefit and for whom extended follow-up is of greater import. We did find that APBI facilities were associated with modestly increased RT use among all patients with invasive disease who live >50 miles from the evaluating RT facility, thereby suggesting that APBI may be attractive for this subgroup. However, despite this finding, it is important to note that the overall impact remained modest. Post hoc analyses also revealed some small temporal changes in the use of HF-WBI and APBI. However, these changes were too small to allow for any definitive conclusions to be made regarding their effect on adjuvant RT use over time. Regardless of the analyses that we undertook, there remained a firm contingent of women (between 22%-25%) who did not receive RT. We hypothesized that there are likely other factors that we were unable to measure that accounted for the slight changes in adjuvant RT use observed during our study period. Although patterns of use of HF-WBI and APBI may contribute to changes in RT use over time, their contribution is likely very minimal given the minute changes we observed, and more research is needed to better understand the drivers for the appropriate use of RT after BCS beyond convenience. We also found that access to APBI facilities was associated with decreased adjuvant RT use among all patients with DCIS. However, risk stratification found that evaluation at APBI facilities was associated with decreased use among patients with standard-risk DCIS and no difference in use among patients with low-risk DCIS, although the clinical impact of this is minimal given the odds ratios observed. It has been hypothesized that APBI facilities, as adopters of newer techniques, may be early adopters in other arenas as well. There could be a higher use of risk stratification tools such as nomograms, 28 gene expression profiling, 29 or prognostic indices 30 among such facilities, resulting in less RT use. In addition, such facilities may be disproportionally more supportive of the relatively new concept that the majority of cases of DCIS are overtreated, such as hypothesized in the Low Risk DCIS (LORIS) trial. 31 If this is the case, APBI facilities may be less likely to offer an intervention such as WBI, with its attendant potential toxicities. This decreased use of RT also could reflect that the treatment of patients with pure DCIS with APBI is considered cautionary by the ASTRO consensus guidelines 14 that were in place during the study period, resulting in the greater reluctance of clinicians to offer this therapy. If this is the case, it is possible that they would prefer to omit RT in this controversial group of patients rather than go against guidelines or administer wholebreast treatment. Finally, because APBI facilities have patients treated with brachytherapy, which requires close collaboration with surgeons, it may be that APBI facilities differ with regard to their referral patterns from surgeons, or that they develop a more surgical-type mindset toward patients with DCIS, favoring the omission of RT. More study is needed to identify which factors account for the decreased RT rates noted among patients with standardrisk DCIS who are evaluated at APBI facilities.
In addition, the results of the current study found that many demographic and facility-related factors influence the use of RT after BCS more than access to APBI. The findings of the current study that nonclinical factors such as race and insurance type are associated with differences in RT use suggest racial and socioeconomic disparities in care. 32, 33 The finding of lower rates of breast RT after BCS in academic facilities may indicate that academic centers care for a larger percentage of patients with poorer health, complex socioeconomic situations, higher financial toxicity from treatment, or a lack of support systems that make those patients more likely to forgo RT.
The findings of the current study suggest that instead of focusing on expanding APBI use to promote increased guideline-concordant RT use, other strategies may prove to be more beneficial. For example, given the current study finding of the importance of geographic factors affecting service, interventions such as providing transportation options to women residing in remote areas or strategic planning for the placement of RT facilities in underserved areas may be beneficial. Implementation of quality improvement programs among cancer centers also could improve care. For example, the promotion of reporting systems such as the Rapid Quality Reporting System (RQRS) 34 that allow for real-time coordination of cancer care and notification of how individual institutions are performing according to national standards could provide local hospitals with an impetus to improve the use of guideline-concordant care.
The current study has several limitations to consider. First, the delivery of APBI depends on the radiation oncologist offering it to the patient and the patient accepting the treatment. Unfortunately, it was not possible for us to assess differences in patient and provider preferences or reimbursement patterns, which could account for the variations found in the current study. Second, the same center could variably be delivering APBI one year and not delivering it the next, and therefore it is difficult to fully control for variations in APBI delivery in each facility. However, we addressed this issue by determining the status of APBI availability in a facility based on their rate of APBI use for a given year, thus accounting for issues such as discontinuation or adoption of APBI by a facility during the study period. We believe that this method best allows us to gain a better understanding of the true association between RT use and actual practice patterns. Third, the NCDB does not specifically indicate whether a patient received APBI or WBI. Rather, we had to define APBI receipt based on the dose and number of fractions received. Although it is possible that some patients were misclassified, the probability is low given that our criteria were very specific and in accordance with definitions used in other studies. This was made stronger by our requirement that APBI be defined as 10 fractions. To the best of our knowledge, there currently is no WBI regimen outside of a clinical trial that prescribes <15 fractions of treatment. Fourth, the majority of patients in the NCDB were missing data regarding hormone receptor status or human epidermal growth factor receptor 2 (HER2) status, and therefore we could not properly assess the influence of these factors on RT use. However, because the vast majority of breast cancer cases diagnosed among elderly women are either ER positive or progesterone receptor positive, it is unlikely that our decision to classify women as low risk if they had ER-positive disease or disease of unknown ER status, along with other criteria, resulted in the misclassification of a significant number of women. In addition, this failure to report ER status is unlikely to vary across facilities. There also were important provider-level variables that are not recorded in the NCDB, such as for-profit facility status, years of practice, practice disease site focus, and complication rates, which could influence provider attitudes toward RT after BCS. Finally, there was likely regional variation in the underascertainment of RT after BCS in the NCDB, as has been shown in other national and state cancer registries. 35 However, it is unlikely that underascertainment differentially impacted one type of facility over another, and therefore its effects on our conclusions regarding the association between APBI availability and RT receipt are likely minimal.
The results of the current study demonstrated no difference in RT use after BCS for eligible patients treated in APBI facilities, including the subgroup of patients with standard-risk invasive cancer. However, we noted mixed patterns for patients who may derive less benefit from adjuvant RT, with increased RT use observed in patients with low-risk invasive cancer but decreased RT use noted among patients with standard-risk DCIS. Increasing access to shorter fractionation schemes, such as with APBI, appears unlikely to improve rates of adjuvant RT use among patients who would most benefit from treatment.
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